Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Penpulimab in Advanced NSCLC
NCT06341530Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, penpulimab in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Jan 2024; status: recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06341530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341530.